Your Messages Inbox
Your Article Summary
See Latest ArticlesWatson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Watson Pharmaceuticals, 04/08/09
Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced that RAPAFLO(TM), the company's new, uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia, is available for patients by prescription. Watson received U.S. Food and Drug Administration (FDA) approval for RAPAFLO in October 2008.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09
Urinary Diversion Trends at a High Volume, Single American Tertiary Care Center
The Journal of Urology, 11/02/09
Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09
Article Search
Sponsor